Cosmetic manufacturing RFQ: separate formula, batch and regulatory handoffs
A manufacturing quote should explain what information the manufacturer supplies to the responsible person and qualified safety assessor. The acquired EU provisions connect GMP, a product-attributable file and safety/claim evidence. An own-brand or private-label arrangement can change the actor role; choosing a factory does not settle the complete regulatory handoff.
Evidence retrieved 2026-10-06. Source versions and topic-specific limits are listed below.
Sourced criteria · EU
What changes the service scope?
Decision or task
What the source describes
What to prepare
Which actor owns the brand and regulatory role?
Article 4(6) describes a distributor’s own-name/trademark or compliance-affecting modification, while other paragraphs address manufacture and import. [1]
Record brand, legal manufacturer/importer and who accepts the role. Agree formula/document access and commercial ownership expressly; these ownership terms are RFQ decisions, not inferred statutory requirements.
What manufacturing evidence is supplied?
Article 8 describes GMP; Article 11(2)(c) links the manufacturing method and GMP compliance statement to the product information file. [2][4]
Ask for the actual process/GMP evidence, batch traceability and change notifications for the quoted product. Do not infer certification from directory membership.
Which formula and exposure facts reach the assessor?
Article 10 specifies assessment of intended use and anticipated systemic exposure to ingredients in the final formulation. [3]
Agree delivery of the quantitative formula and supplier evidence to the qualified assessor, including confidential-access arrangements.
Which claims and changes affect the handoff?
Article 11 specifies product attribution and, where justified, claimed-effect evidence; Article 10 requires updating the safety report in view of additional information. [3][4]
Define the quoted product/version, supported claims, change approval and which revised documents are handed over.
This is an EU evidence-handoff guide, not proof of a vendor’s capabilities, availability, GMP certification or a safe formula. UK requirements and actual vendor statements require separate evidence.
A scoped evidence and handoff plan
Use this checklist to gather your business or product details before speaking with a specialist. The items below explain what to record and suggest useful supporting documents. You can add your own answers in the editable project brief.
Which actor owns the brand and regulatory role?
Record brand, legal manufacturer/importer and who accepts the role. Agree formula/document access and commercial ownership expressly; these ownership terms are RFQ decisions, not inferred statutory requirements.
Useful evidence: Brand/actor map, parties, formula access/ownership terms and mandate where applicable.
What manufacturing evidence is supplied?
Ask for the actual process/GMP evidence, batch traceability and change notifications for the quoted product. Do not infer certification from directory membership.
Which formula and exposure facts reach the assessor?
Agree delivery of the quantitative formula and supplier evidence to the qualified assessor, including confidential-access arrangements.
Useful evidence: Formula/version, raw-material identity/specification, intended use/exposure and assessor access.
Which claims and changes affect the handoff?
Define the quoted product/version, supported claims, change approval and which revised documents are handed over.
Useful evidence: Product/label/claim version, relevant claim evidence and formula/process-change log.
Work packages and dependencies
Conditional: Formula, manufacturing and controlled evidence-handoff RFQ — For this work package, agree the supported criteria, evidence access, covered entities/products and unresolved facts in the table above. Additional services require their own justified scope.
Optional: Separate responsible-person, safety-file and notification scope — For this work package, agree the supported criteria, evidence access, covered entities/products and unresolved facts in the table above. Additional services require their own justified scope.
Questions for providers
Which exact actor, product or processing facts support the quoted scope, and what is still unresolved?
How will the listed records reach the responsible people, and who owns each change or authority request?
Which tasks and entities are excluded from the agreement, and which additional services need a separate assessment?
Sources and data dates
Read the official document in context. The audit details identify the precise locators and preserved versions used for this page.
